Supernus Pharmaceuticals Total Liabilities and Share Holders Equity 2011-2024 | SUPN
Supernus Pharmaceuticals total liabilities and share holders equity from 2011 to 2024. Total liabilities and share holders equity can be defined as the total of all liabilities and shareholders' equity.
Supernus Pharmaceuticals Annual Total Liabilities and Share Holders Equity
(Millions of US $) |
| 2023 |
$1,278 |
| 2022 |
$1,703 |
| 2021 |
$1,689 |
| 2020 |
$1,504 |
| 2019 |
$1,160 |
| 2018 |
$978 |
| 2017 |
$424 |
| 2016 |
$310 |
| 2015 |
$189 |
| 2014 |
$137 |
| 2013 |
$111 |
| 2012 |
$94 |
| 2011 |
$54 |
| 2010 |
$0 |
Supernus Pharmaceuticals Quarterly Total Liabilities and Share Holders Equity
(Millions of US $) |
| 2024-09-30 |
$1,343 |
| 2024-06-30 |
$1,316 |
| 2024-03-31 |
$1,304 |
| 2023-12-31 |
$1,278 |
| 2023-09-30 |
$1,285 |
| 2023-06-30 |
$1,293 |
| 2023-03-31 |
$1,792 |
| 2022-12-31 |
$1,703 |
| 2022-09-30 |
$1,693 |
| 2022-06-30 |
$1,695 |
| 2022-03-31 |
$1,640 |
| 2021-12-31 |
$1,689 |
| 2021-09-30 |
$1,555 |
| 2021-06-30 |
$1,573 |
| 2021-03-31 |
$1,507 |
| 2020-12-31 |
$1,504 |
| 2020-09-30 |
$1,510 |
| 2020-06-30 |
$1,491 |
| 2020-03-31 |
$1,190 |
| 2019-12-31 |
$1,160 |
| 2019-09-30 |
$1,107 |
| 2019-06-30 |
$1,064 |
| 2019-03-31 |
$1,025 |
| 2018-12-31 |
$978 |
| 2018-09-30 |
$923 |
| 2018-06-30 |
$853 |
| 2018-03-31 |
$825 |
| 2017-12-31 |
$424 |
| 2017-09-30 |
$385 |
| 2017-06-30 |
$346 |
| 2017-03-31 |
$322 |
| 2016-12-31 |
$310 |
| 2016-09-30 |
$285 |
| 2016-06-30 |
$219 |
| 2016-03-31 |
$194 |
| 2015-12-31 |
$189 |
| 2015-09-30 |
$167 |
| 2015-06-30 |
$154 |
| 2015-03-31 |
$139 |
| 2014-12-31 |
$137 |
| 2014-09-30 |
$126 |
| 2014-06-30 |
$94 |
| 2014-03-31 |
$98 |
| 2013-12-31 |
$111 |
| 2013-09-30 |
$124 |
| 2013-06-30 |
$132 |
| 2013-03-31 |
$79 |
| 2012-12-31 |
$94 |
| 2012-09-30 |
$67 |
| 2012-06-30 |
$80 |
| 2012-03-31 |
$43 |
| 2011-12-31 |
$54 |
| 2011-09-30 |
$0 |
| 2011-06-30 |
$0 |
| 2011-03-31 |
$0 |
| 2010-12-31 |
$0 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$1.962B |
$0.608B |
|
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.
|
